Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Statin, metformin lower mortality in high-risk prostate cancer 

Key clinical point: Statin use alone or in combination with metformin reduces mortality in patients with high-risk prostate cancer.

Major finding: Statins alone and in combination with metformin significantly lowered all-cause mortality (adjusted hazard ratio [aHR], 0.89 and 0.75; both P less than .01, respectively) and cancer-specific mortality (aHR, 0.80 and 0.64; both P less than .01, respectively).

Study details: Retrospective study of 12,700 patients with high-risk prostate cancer (statin users, n=5786; metformin users, n=435; metformin + statin, n=1911; no metformin/no statin, n=435)

Disclosures: This study was supported by Rutgers Cancer Institute of New Jersey, National Cancer Institute, Sidney Kimmel Foundation for Cancer Research, and Pennsylvania Department of Health. The authors declared no conflicts of interest.

Citation:

Tan XL et al. Cancer Med. 2020 Feb 8. doi: 10.1002/cam4.2862.